In The News: Chambers-Grundy Center for Transformative Neuroscience
Practical Neurology
Aducanumab is the first disease-modifying treatment to be approved for Alzheimer's Disease (AD) and the first to target amyloid ß (Aß), which is one of the earliest causative steps in the pathophysiology of AD.
